Center for Research in Molecular Medicine, The University of Lahore, Lahore, Pakistan.
Arch Pharm Res. 2015 Aug;38(8):1455-67. doi: 10.1007/s12272-014-0523-1. Epub 2014 Nov 30.
Some antimalarial agents in use typically bear basic side chains as ligands. Such ligands were attached to the amino substituent of a bridgehead atom of already antiprotozoal active 3-azabicyclo[3.2.2]nonanes. Structure verification was done by NMR measurements. The new compounds were tested for their antiplasmodial and antitrypanosomal activities against Plasmodium falciparum K 1 (multiresistant) and Trypanosoma brucei rhodesiense as well as for their cytotoxicity against L6 cells. Their activities are compared to those of already prepared compounds and structure-activity relationships are discussed.
一些现有的抗疟药物通常带有作为配体的基本侧链。这些配体被连接到已经具有抗原生动物活性的 3-氮杂双环[3.2.2]壬烷的桥头原子的氨基取代基上。结构验证通过 NMR 测量完成。新化合物针对抗药性疟原虫 falciparum K 1(多耐药性)和非洲锥虫 brucei rhodesiense 进行了抗疟原虫和抗锥虫活性测试,以及对 L6 细胞的细胞毒性测试。将它们的活性与已经制备的化合物进行比较,并讨论了结构-活性关系。